One Pot Stock Could Skyrocket With Looming Interstate Sales
A new bill in Congress would decriminalize marijuana nationally by removing cannabis from the federal government’s list of controlled substances. The law would also allow one established Seattle cannabis company to market across state lines for the first time – potentially setting off a bidding war that could blast this stock into the stratosphere!
Find Out Why This Could Be the #1 Pot Stock
Glenn Goddard, insider at Intellia Therapeutics
Glenn Goddard Insider Alerts

Get notified the next time Glenn Goddard buys or sells Intellia Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Glenn Goddard Insider Information

Glenn Goddard has nearly two decades of experience leading business and financial operations for public and private companies in the biotechnology industry. Prior to joining Intellia, Glenn served as the Chief Financial Officer at Generation Bio Company, where he led all financial functions, investor relations, information technologies and certain operational functions. During his time at Generation Bio, he closed a $100 million private financing and a long-term lease deal for 75,000 square feet of lab and office space. Before joining Generation Bio, Glenn served as Senior Vice President of Finance and Principal Financial Officer of Agios Pharmaceuticals, where he led the company’s strategic financings efforts raising more than $700 million in equity financings, including a private crossover financing, an initial public offering and several subsequent follow-on offerings. In addition, Glenn was responsible for all financial functions of the company, including strategic planning and analysis, investor relations, treasury, tax, finance and accounting. He also was responsible for information technologies, certain operational functions and supporting strategic partnering efforts.

Previously, Glenn held various senior-level financial management positions at both Archemix, a privately held oligonucleotide platform-based biopharmaceutical company, and Immunogen, a publicly traded oncology-focused biopharmaceutical company. Earlier in his career, Glenn was an audit supervisor at Ernst & Young LLP and a business advisory manager at Feeley & Driscoll, P.C. Glenn is a graduate of Bentley College, where he earned a B.S. in Accountancy and is a Certified Public Accountant in the Commonwealth of Massachusetts.

What is Glenn Goddard's salary?

As the CFO of Intellia Therapeutics, Inc., Mr. Goddard earned a total compensation package of $1,563,511.00 in 2020. Mr. Goddard earned a salary of $407,000.00, a bonus of $146,520.00, options awards of $1,001,063.00, and other compensation of $8,928.00.

How do I contact Glenn Goddard?

The corporate mailing address for Mr. Goddard and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at [email protected]

Has Glenn Goddard been buying or selling shares of Intellia Therapeutics?

Glenn Goddard has not been actively trading shares of Intellia Therapeutics within the last three months. Most recently, Glenn Goddard sold 3,482 shares of the business's stock in a transaction on Tuesday, September 7th. The shares were sold at an average price of $180.12, for a transaction totalling $627,177.84.

Who are Intellia Therapeutics' active insiders?

Intellia Therapeutics' insider roster includes John Crowley (Director), Jean-Francois Formela (Director), Glenn Goddard (CFO), David Lebwohl (EVP), John Leonard (CEO), and Laura Sepp-Lorenzino (EVP).

Are insiders buying or selling shares of Intellia Therapeutics?

In the last year, insiders at the sold shares 34 times. They sold a total of 2,182,245 shares worth more than $212,298,922.99. The most recent insider tranaction occured on November, 5th when EVP David Lebwohl sold 2,400 shares worth more than $318,528.00. Insiders at Intellia Therapeutics own 3.9 % of the company.

Information on this page was last updated on 11/5/2021.

Glenn Goddard Insider Trading History at Intellia Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/7/2021Sell3,482$180.12$627,177.84View SEC Filing Icon  
8/31/2021Sell24,800$160.22$3,973,456.00View SEC Filing Icon  
8/5/2021Sell20,000$151.05$3,021,000.00View SEC Filing Icon  
See Full Table

Glenn Goddard Buying and Selling Activity at Intellia Therapeutics

This chart shows Glenn Goddard's buying and selling at Intellia Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intellia Therapeutics Company Overview

Intellia Therapeutics logo
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $111.73
Low: $109.75
High: $117.60

50 Day Range

MA: $132.16
Low: $111.73
High: $155.26

2 Week Range

Now: $111.73
Low: $37.00
High: $202.73

Volume

604,926 shs

Average Volume

1,489,341 shs

Market Capitalization

$8.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.03
One Pot Stock Could Skyrocket With Looming Interstate Sales
A new bill in Congress would decriminalize marijuana nationally by removing cannabis from the federal government’s list of controlled substances. The law would also allow one established Seattle cannabis company to market across state lines for the first time – potentially setting off a bidding war that could blast this stock into the stratosphere!
Find Out Why This Could Be the #1 Pot Stock